Dr Zietman received his undergraduate training at Oxford University in the UK and then went to medical school at the Middlesex Hospital, London University graduating in 1983. After residencies in internal medicine and clinical oncology he moved to the Massachusetts General Hospital in Boston, USA for a fellowship in radiation biology. Since joining the staff he has authored over 100 original articles and reviews on many aspects of GU cancer. His particular research interests are in the specific roles of active surveillance, brachytherapy, hormone therapy, and proton beam therapy in the treatment of prostate cancer. He also has a long-standing interest in the organ-sparing management of bladder cancer. He is currently the Jenot and William Shipley Professor of Radiation Oncology at Harvard Medical School, President of the American Society for Radiation Oncology (ASTRO), and a trustee of the American Board of Radiology.
Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS, Barry MJ, Zietman A.L., O'Leary M, Walker-Corkery E, Yao SL. Outcomes of localized prostate cancer following conservative management. JAMA 16:302 1202-9 2009
Zietman A.L., Bae K., Slater J.D., Shipley W.U., Efstathiou J.A., Coen J.J., Bush D.A., Lunt M., Spiegel D.Y., Skowronski R., Jabola B.R., Rossi C.J. A randomized trial comparing conventional dose conformal radiation therapy with high-dose in early stage adenocarcinoma of the prostate. Long-term results from Proton Radiaiton Oncology Group (PROG)/American College of Radiology (ACR) 95-09. J. Clin. Oncol. (in press) 2009.
Zietman A.L.. The Titanic and The Iceberg: prostate proton therapy and healthcare economics. J. Clin. Oncol. 25: 3565-66, 2007.
Zietman A.L.. Evidence-based medicine, conscience-based medicine, and the management of low-risk prostate cancer.J. Clin Oncol. 27:4935-6, 2009